Molbio Diagnostics' initial public offering (IPO) has entered its second day of bidding, with the grey market continuing to indicate a premium listing despite fluctuations in sentiment over the past week. While the issue was not fully subscribed on the opening day, several brokerage firms remain optimistic about the company's long-term growth prospects.
Investors are evaluating the IPO based on its listing gain potential, molecular diagnostics leadership, recurring revenue model and valuation before making an investment decision.
Molbio Diagnostics IPO details
The Rs 939.70 crore IPO opened for subscription on August 10, 2026, and will close on August 12, 2026.
IPO Highlights
-
Price Band: Rs 768–807 per share
-
Lot Size: 18 shares
-
Minimum Investment: Rs 14,526
-
Issue Size: Rs 939.70 crore
-
Fresh Issue: Rs 200 crore
-
Offer for Sale (OFS): Rs 739.70 crore
-
Expected Listing Date: August 17, 2026
-
Stock Exchanges: NSE and BSE
Molbio Diagnostics IPO GMP today
The latest Grey Market Premium (GMP) stands at Rs 127.
Based on the upper issue price of Rs 807, the GMP indicates an estimated listing price of around Rs 934, suggesting a potential listing gain of nearly 15.7% if the premium remains unchanged.
However, investors should note that GMP reflects unofficial market sentiment and does not guarantee the actual listing price.
The grey market premium has remained volatile during the IPO period, indicating changing investor expectations ahead of listing.
Subscription status after Day 1
The IPO received a moderate response during the first day of bidding.
Subscription details:
-
Overall subscription: 0.83 times
-
Retail Investors: 0.77 times
-
Qualified Institutional Buyers (QIB): 1.00 time (excluding anchor investors)
-
Non-Institutional Investors (NII): 0.73 times
Market participants will closely monitor subscription levels during the remaining bidding period, particularly institutional demand.
What does Molbio Diagnostics do?
Molbio Diagnostics is a leading molecular diagnostics company focused on developing rapid and portable diagnostic solutions.
Its flagship Truenat platform enables point-of-care molecular testing and is used for detecting multiple infectious diseases, including:
-
Tuberculosis (TB)
-
HIV
-
Hepatitis
-
Human Papillomavirus (HPV)
-
COVID-19
-
Several other infectious diseases
The company combines diagnostic devices with proprietary test kits, creating a recurring revenue business model.
Recurring revenue model strengthens business
One of Molbio's biggest strengths is its integrated diagnostics ecosystem.
After installing diagnostic devices, healthcare providers continue purchasing the company's proprietary test kits and consumables, generating recurring revenue over the long term.
This business model improves revenue visibility and supports sustained growth as the installed base expands across hospitals, laboratories and healthcare institutions.
Financial performance
Molbio Diagnostics has reported healthy financial growth in recent years.
Key highlights include:
-
Strong revenue growth
-
Rising EBITDA
-
Higher adjusted profit after tax
-
Significant increase in diagnostic test-kit volumes
Despite strong top-line growth, profitability margins have moderated due to higher operating costs and business expansion.
Is the IPO fairly valued?
At the upper price band, the company is valued at around 55–56 times FY26 earnings.
Several brokerage firms consider the valuation reasonable, citing:
-
Leadership in molecular diagnostics
-
Proprietary technology platform
-
Strong growth potential
-
Recurring consumables business
-
Expanding healthcare diagnostics market
Although the valuation is not inexpensive, analysts believe it is supported by the company's long-term growth opportunities.
Key risks investors should consider
Before investing, investors should carefully assess several business risks.
Major concerns include:
-
High dependence on government and institutional customers
-
Significant reliance on tuberculosis (TB) diagnostics
-
Moderating EBITDA and profit margins
-
Long working capital cycle
-
Customer concentration risk
The company's ability to diversify its customer base and disease portfolio will be important for sustaining long-term growth.
Should you subscribe to the Molbio Diagnostics IPO?
The IPO offers attractive long-term opportunities in India's growing healthcare diagnostics sector.
A positive grey market premium indicates healthy listing expectations, while the company's proprietary technology, recurring revenue model and leadership in molecular diagnostics strengthen its investment case.
However, investors should avoid making decisions based solely on GMP. Valuation, customer concentration, margin trends and execution risks should also be considered.
Overall, the IPO appears suitable for investors with a medium- to long-term investment horizon, while listing gains will ultimately depend on market conditions at the time of debut.
Key Highlights
-
Molbio Diagnostics IPO entered Day 2 with a GMP of Rs 127.
-
The GMP indicates a potential listing gain of around 15.7%.
-
The IPO closes on August 12, with listing expected on August 17.
-
Day 1 subscription stood at 0.83 times.
-
Molbio is a leading molecular diagnostics company with the proprietary Truenat platform.
-
The company benefits from a recurring revenue model through diagnostic test kits.
-
Several brokerages have recommended subscribing to the IPO for the long term.
-
Investors should also consider risks including customer concentration and margin moderation.
FAQs
1. What is the latest GMP of Molbio Diagnostics IPO?
The latest Grey Market Premium (GMP) is Rs 127.
2. What listing gain does the current GMP indicate?
Based on the upper issue price, the GMP suggests a potential listing gain of approximately 15.7%, although this is not guaranteed.
3. What is the price band of the IPO?
The IPO price band is Rs 768 to Rs 807 per share.
4. When does the IPO close?
The issue closes for subscription on August 12, 2026.
5. When is Molbio Diagnostics expected to list?
The shares are expected to list on August 17, 2026, on NSE and BSE.
6. What does Molbio Diagnostics do?
The company develops molecular diagnostic devices and proprietary test kits for detecting infectious diseases through its Truenat platform.
7. Why is Molbio's business model considered attractive?
Its recurring revenue model generates continuous demand for proprietary diagnostic test kits after device installations.
8. What are the major risks in the IPO?
Key risks include dependence on government customers, concentration in TB diagnostics, moderating margins and working capital requirements.
9. Is the IPO expensive?
The IPO is valued at around 55–56 times FY26 earnings, which analysts generally consider reasonable given the company's market position and growth prospects.
10. Should investors subscribe to the IPO?
Several brokerages have recommended subscribing for a medium- to long-term investment horizon. Investors should evaluate both growth opportunities and business risks before investing.
